G, S., AM, v. d. H., D, D. T., EJ, P., S, S. V., B, B., . . . DA, F. (2020). Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver international : official journal of the International Association for the Study of the Liver, 40(11), 2860. https://doi.org/10.1111/liv.14643
Chicago Style (17th ed.) CitationG, Stokman, et al. "Dual Targeting of Hepatic Fibrosis and Atherogenesis by Icosabutate, an Engineered Eicosapentaenoic Acid Derivative." Liver International : Official Journal of the International Association for the Study of the Liver 40, no. 11 (2020): 2860. https://doi.org/10.1111/liv.14643.
MLA (9th ed.) CitationG, Stokman, et al. "Dual Targeting of Hepatic Fibrosis and Atherogenesis by Icosabutate, an Engineered Eicosapentaenoic Acid Derivative." Liver International : Official Journal of the International Association for the Study of the Liver, vol. 40, no. 11, 2020, p. 2860, https://doi.org/10.1111/liv.14643.
